FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801151975> ?p ?o ?g. }

• W2801151975 endingPage "330" @default.
• W2801151975 startingPage "322" @default.
• W2801151975 abstract "Objective: To examine status of children with autism spectrum disorder (ASD) 10 months after a 34-week clinical trial of atomoxetine (ATX) and parent training (PT). Methods: In a 2 × 2 design, 128 children with ASD and attention-deficit/hyperactivity disorder (ADHD) were randomly assigned ATX, PT+placebo, PT+ATX, or placebo alone. PT was weekly for 10 weeks, and then monthly. ATX/placebo was titrated over 6 weeks [≤1.8 mg/kg/d], and then maintained until week 10. Responders continued to week 34 or nonresponse. Placebo nonresponders had a 10-week ATX open trial; ATX nonresponders were treated clinically. All continued to week 34. With no further treatment from the study, all were invited to follow-up (FU) at 1.5 years postbaseline; 94 (73%) participated. Changes from Week 34 to FU and from baseline to FU were tested by one-way analysis of variance or chi-squared test. PT versus no PT was tested by chi-squared test, Fisher's exact test, Welch's t-test, Student's t-test, and Mann–Whitney's U test. Results: For the whole sample, the primary outcomes (parent-rated ADHD on the Swanson, Nolan, and Pelham [SNAP] scale and noncompliance on the Home Situations Questionnaire [HSQ]) deteriorated mildly from week 34 to FU, but were still substantially better than baseline (SNAP: t = 12.177, df = 93, p < 0.001; HSQ: t = 8.999, df = 93, p < 0.001). On the SNAP, 61% improved ≥30% from baseline (67% did at week 34); on noncompliance, 56% improved ≥30% from baseline (77% did at week 34). Outcomes with PT were not significantly better than without PT (SNAP p = 0.30; HSQ p = 0.27). Originally assigned treatment groups did not differ significantly. Only 34% still took ATX; 27% were taking stimulants; and 25% took no medication. Conclusions: The majority retained their 34-week end-of-study improvement 10 months later, even though most participants stopped ATX. For some children, ATX continuation may not be necessary for continued benefit or other drugs may be necessary. Cautious individual clinical experimentation may be justified. Twelve sessions of PT made little long-term difference. ClinicalTrials.gov Identifier: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) (NCT00844753)." @default.
• W2801151975 created "2018-05-17" @default.
• W2801151975 creator A5008552659 @default.
• W2801151975 creator A5014323094 @default.
• W2801151975 creator A5023681590 @default.
• W2801151975 creator A5035236451 @default.
• W2801151975 creator A5052005476 @default.
• W2801151975 creator A5053767867 @default.
• W2801151975 creator A5061235868 @default.
• W2801151975 creator A5069598980 @default.
• W2801151975 creator A5080756501 @default.
• W2801151975 creator A5085837797 @default.
• W2801151975 creator A5087993762 @default.
• W2801151975 date "2018-06-01" @default.
• W2801151975 modified "2023-10-01" @default.
• W2801151975 title "A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism" @default.
• W2801151975 cites W1561051627 @default.
• W2801151975 cites W1731081963 @default.
• W2801151975 cites W1763341610 @default.
• W2801151975 cites W1931362782 @default.
• W2801151975 cites W1973669208 @default.
• W2801151975 cites W1985610903 @default.
• W2801151975 cites W2006481048 @default.
• W2801151975 cites W2011399660 @default.
• W2801151975 cites W2024770504 @default.
• W2801151975 cites W2036593899 @default.
• W2801151975 cites W2069917423 @default.
• W2801151975 cites W2069931937 @default.
• W2801151975 cites W2077263553 @default.
• W2801151975 cites W2124620143 @default.
• W2801151975 cites W2137561005 @default.
• W2801151975 cites W2144385879 @default.
• W2801151975 cites W2158063953 @default.
• W2801151975 cites W2162520210 @default.
• W2801151975 cites W2167767364 @default.
• W2801151975 cites W2340054991 @default.
• W2801151975 cites W2479069490 @default.
• W2801151975 cites W2559500546 @default.
• W2801151975 cites W2614580325 @default.
• W2801151975 cites W4247665917 @default.
• W2801151975 doi "https://doi.org/10.1089/cap.2017.0134" @default.
• W2801151975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5994674" @default.
• W2801151975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29694241" @default.
• W2801151975 hasPublicationYear "2018" @default.
• W2801151975 type Work @default.
• W2801151975 sameAs 2801151975 @default.
• W2801151975 citedByCount "9" @default.
• W2801151975 countsByYear W28011519752018 @default.
• W2801151975 countsByYear W28011519752019 @default.
• W2801151975 countsByYear W28011519752020 @default.
• W2801151975 countsByYear W28011519752021 @default.
• W2801151975 countsByYear W28011519752022 @default.
• W2801151975 countsByYear W28011519752023 @default.
• W2801151975 crossrefType "journal-article" @default.
• W2801151975 hasAuthorship W2801151975A5008552659 @default.
• W2801151975 hasAuthorship W2801151975A5014323094 @default.
• W2801151975 hasAuthorship W2801151975A5023681590 @default.
• W2801151975 hasAuthorship W2801151975A5035236451 @default.
• W2801151975 hasAuthorship W2801151975A5052005476 @default.
• W2801151975 hasAuthorship W2801151975A5053767867 @default.
• W2801151975 hasAuthorship W2801151975A5061235868 @default.
• W2801151975 hasAuthorship W2801151975A5069598980 @default.
• W2801151975 hasAuthorship W2801151975A5080756501 @default.
• W2801151975 hasAuthorship W2801151975A5085837797 @default.
• W2801151975 hasAuthorship W2801151975A5087993762 @default.
• W2801151975 hasBestOaLocation W28011519751 @default.
• W2801151975 hasConcept C102959455 @default.
• W2801151975 hasConcept C105795698 @default.
• W2801151975 hasConcept C118552586 @default.
• W2801151975 hasConcept C126322002 @default.
• W2801151975 hasConcept C12868164 @default.
• W2801151975 hasConcept C142724271 @default.
• W2801151975 hasConcept C15744967 @default.
• W2801151975 hasConcept C191093355 @default.
• W2801151975 hasConcept C204787440 @default.
• W2801151975 hasConcept C27081682 @default.
• W2801151975 hasConcept C2777112843 @default.
• W2801151975 hasConcept C2778781522 @default.
• W2801151975 hasConcept C2780783007 @default.
• W2801151975 hasConcept C2909253567 @default.
• W2801151975 hasConcept C33923547 @default.
• W2801151975 hasConcept C71924100 @default.
• W2801151975 hasConcept C99476002 @default.
• W2801151975 hasConceptScore W2801151975C102959455 @default.
• W2801151975 hasConceptScore W2801151975C105795698 @default.
• W2801151975 hasConceptScore W2801151975C118552586 @default.
• W2801151975 hasConceptScore W2801151975C126322002 @default.
• W2801151975 hasConceptScore W2801151975C12868164 @default.
• W2801151975 hasConceptScore W2801151975C142724271 @default.
• W2801151975 hasConceptScore W2801151975C15744967 @default.
• W2801151975 hasConceptScore W2801151975C191093355 @default.
• W2801151975 hasConceptScore W2801151975C204787440 @default.
• W2801151975 hasConceptScore W2801151975C27081682 @default.
• W2801151975 hasConceptScore W2801151975C2777112843 @default.
• W2801151975 hasConceptScore W2801151975C2778781522 @default.
• W2801151975 hasConceptScore W2801151975C2780783007 @default.
• W2801151975 hasConceptScore W2801151975C2909253567 @default.
• W2801151975 hasConceptScore W2801151975C33923547 @default.

• next